Substituted hydantoins

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C548S146000, C548S190000, C548S193000, C548S194000, C548S195000

Reexamination Certificate

active

07427635

ABSTRACT:
The present invention relates to compounds of the formulawhich are useful in treating diseases characterized by the hyperactivity of MEK.Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.

REFERENCES:
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 6583288 (2003-06-01), Goodnow et al.
patent: 6784298 (2004-08-01), Goodnow et al.
patent: WO 99/01426 (1999-01-01), None
patent: WO 01/83478 (2001-11-01), None
patent: WO 03/008365 (2003-01-01), None
J. M. English et al.,Trends in Pharm. Sci. 2002, 23(1), 40.
J. L. Bos,Cancer Res. 1989, 49, 4682.
A. Bonni et al,Science1999, 286, 1358.
H. Davies et al.Nature2002, 417, 949.
R. Herrera et al.Trends Mol. Med. 2002,8(4, Suppl.), S27.
C. F. Zheng et al.,J. Biol. Chem. 1993, 268, 11435.
S. Cowley et al.,Cell1994, 77, 841.
R. Seger et al.,J. Biol. Chem. 1992, 267, 14373.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Substituted hydantoins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted hydantoins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted hydantoins will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3965405

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.